Core Insights - Fangzhou Inc. has launched its proprietary "XingShi" Large Language Model (XS LLM) aimed at improving chronic disease management through enhanced service efficiency and personalization [1][4] - The XS LLM integrates multimodal capabilities including image and speech recognition, natural language processing, and large-scale medical knowledge storage, supporting five domain-specific intelligent agents [2] - The model serves as the core digital brain of Fangzhou's platform, powering five AI-enabled applications that facilitate real-time interventions in medication guidance, patient education, and diagnostic assistance [3] Company Overview - Fangzhou Inc. is a leading online chronic disease management platform in China, with 52.8 million registered users and 229,000 physicians as of June 30, 2025 [5] - The company specializes in tailored medical care and AI-enabled precision medicine solutions, reflecting its commitment to scalable and accessible healthcare delivery [4][5]

董事会亦留意到，公司就其于2025年9月10日举行的第十届H2H医疗服务生态大会而刊发的新闻稿，其 中包括若干公司最新消息，包括(i)公司发布专有「杏石」大模型("杏石大模型")作为其五项旗舰应用(AI 用药助手、AI健康管家、AI医生助手、AI学术助手及AI搜索)的基石，赋能先进临床诊断支援及个性化 慢病管理；(ii)与信达生物制药("信达")达成战略合作伙伴关系，整合方舟H2H数字健康生态系统与信达 体重管理疗法管线，初步利用公司之杏石大模型，为信达的玛仕度肽提供个性化数字维护及依从性支 持，在中国快速增长的体重管理市场提高患者的疗效；及(iii)与浙江大塚制药有限公司("大塚")展开战略 合作，结合公司的AI技术优势及大塚的创新药组合，共同开发覆盖药物支援服务、针对性病患外展项 目及健康教育计划的全方位数字解决方案。 经作出在相关情况下有关公司的该等合理查询后，董事会确认(i)新闻稿所含资料并不构成根据上市规则 第13.09(2)条或香港法例第571章证券及期货条例第XIVA部项下之内幕消息条文所规定之内幕消息；及 (ii)其亦并不知悉股份交易价格上升之任何理由，或为避免股份出现虚假市场而须作出公告之任 ...

Core Viewpoint - Ark Health (06086) has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025, following the announcement of its strategic initiatives and partnerships in the healthcare sector [1]. Group 1: Company Developments - The company has launched its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications, including AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search, aimed at enhancing clinical diagnostic support and personalized chronic disease management [1]. - Ark Health has formed a strategic partnership with Innovent Biologics to integrate its H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model to provide personalized digital maintenance and adherence support for Innovent's Ma Shidu peptide in China's rapidly growing weight management market [1]. - The company has also entered into a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., combining its AI technology advantages with Otsuka's innovative drug portfolio to jointly develop comprehensive digital solutions covering drug support services, targeted patient outreach programs, and health education initiatives [1]. Group 2: Regulatory Confirmation - The board has confirmed that the information contained in the press release does not constitute inside information as defined under the Listing Rules and relevant securities regulations, and it is unaware of any reasons for the increase in share price or any information that needs to be disclosed to avoid creating a false market in its shares [2].

Group 1 - The company, Ark Health (06086), has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025 [1] - The company announced its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications aimed at enhancing clinical diagnostic support and personalized chronic disease management [1] - A strategic partnership has been established with Innovent Biologics to integrate Ark's H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model for personalized digital maintenance and compliance support in China's growing weight management market [1] - The company has also formed a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., Ltd. to develop comprehensive digital solutions that combine AI technology with Otsuka's innovative drug portfolio, focusing on drug support services, targeted patient outreach programs, and health education initiatives [1] Group 2 - The board confirmed that the information contained in the press release does not constitute insider information as defined under the relevant listing rules and securities regulations [2] - The board is not aware of any reasons for the increase in share price or any information that would require disclosure to prevent a false market in the shares [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不會就本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公司股東及潛在投資者於買賣股份時務請審慎行事。 本公告乃根據本公司之命令而作出。董事會就本公告之準確性全體及個別承 擔責任。 承董事會命 Fangzhou Inc. 方舟云康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6086） 根據上市規則第13.10條作出之公告 本公告乃應香港聯合交易所有限公司（「聯交所」）要求根據聯交所證券上市 規則（「上市規則」）第13.10條作出。方舟云康控股有限公司（「本公司」）董 事會（「董事會」）留意到，本公司股份（「股份」）近期於2025年9月12日在聯 交所的價格有所上升。 董事會亦留意到，本公司就其於2025年9月10日舉行的第十屆H2H醫療服務 生態大會而刊發的新聞稿（「新聞稿」），其中包括若干本公司之最新消息， 包括(i)本公司發佈專有「杏石」大模型（「杏石大模型」）作為其五項旗艦應用 （AI用藥助手、AI健康管家、AI醫生助手、AI學術助手 ...

Core Insights - Fangzhou Jianke has achieved profitability with a revenue of 1.494 billion yuan, marking a 12.9% growth, and a net profit of 12.5 million yuan as of mid-2025 [3] - The company employs a "familiar doctor-patient" model, focusing on relationship reconstruction rather than merely chasing traffic [4][5] - The AI-powered "Xing Shi Medical Model" aims to enhance the efficiency of its H2H (Hospital to Home) healthcare ecosystem [6][9] Company Performance - Fangzhou Jianke's user base has grown to over 52.8 million registered users and 229,000 registered doctors by mid-2025, with a high repurchase rate of 84.7% among paying users [4] - The company’s growth is driven by value-based internal growth, reducing reliance on continuous traffic purchases [5] AI Integration - The "Xing Shi Medical Model" integrates a comprehensive knowledge base from the Chinese Medical Association, covering over 1.1 million articles across 170 core journals [6] - Five core AI products have been launched, creating a collaborative network across medical, patient, and enterprise sectors [7] Efficiency Improvements - The AI Doctor Assistant has saved over 60,000 hours of work for doctors by providing nearly 400,000 technical assists, allowing them to focus on more complex diagnoses [8] - The AI Health Manager has reduced average consultation times by over 70%, significantly enhancing patient experience [8] Future Vision - By 2025, the company aims to integrate AI assistants into daily medical practices, with daily usage exceeding 100,000 times [10] - The ultimate goal is to establish "Fangzhou Medical Smart Cloud" by 2027, serving as an authoritative clinical decision standard across the industry [10]

具体而言，在药事服务领域，依托AI用药助手的实时响应能力，肥胖症患者无需等待即可获得7x24小 时在线咨询、在线找药、用药问答等专业支持，彻底打破传统药事服务的时空限制。在体重管理方面， AI健康管家作为患者的全天候健康管理伙伴，能提供个性化用药指导、服务提醒与管理、报告解读与 知识科普等延伸服务，不仅提供心理上的抚慰，还降低了其决策成本，实现患者健康素养与自我管理能 力有效提升。 消息面上，9月10日，在方舟健客第十届H2H医疗服务生态大会上，国内领先的AI+慢病管理企业方舟 健客与信达生物正式签署战略合作协议。据介绍，方舟健客将依托其AI技术成果、H2H智慧医疗新生态 和数智化行业经验，重塑慢病患者全周期管理流程，构建个性化、一体式的健康管理新体验。基于本次 战略合作的良好开端，双方未来将发挥各自优势，推动创新治疗方案与AI技术驱动的数智化健康管理 深度融合，携手构建"AI+减重"领域的服务新范式。 方舟健客(06086)盘中涨超7%，截至发稿，涨6.65%，报4.65港元，成交额2854.33万港元。 ...

Core Viewpoint - Ark Health (06086) has seen a stock price increase of over 7%, currently trading at 4.65 HKD, following the announcement of a strategic partnership with Innovent Biologics to enhance chronic disease management through AI technology [1] Group 1: Strategic Partnership - Ark Health signed a strategic cooperation agreement with Innovent Biologics at the 10th H2H Medical Service Ecosystem Conference on September 10 [1] - The partnership aims to leverage Ark Health's AI technology and industry experience to reshape the full-cycle management process for chronic disease patients [1] - Both companies will work together to integrate innovative treatment solutions with AI-driven health management [1] Group 2: AI-Driven Services - The collaboration will focus on creating a new service paradigm in the "AI + Weight Loss" sector [1] - In the pharmaceutical service area, the AI medication assistant will provide 24/7 online consultation, medication inquiries, and support for obesity patients without waiting time [1] - The AI health manager will serve as a round-the-clock health management partner, offering personalized medication guidance, service reminders, and educational resources to enhance patient self-management capabilities [1]

9月10日，方舟健客第十届 H2H 医疗服务生态大会在上海举办。会上，方舟健客(06086.HK)重磅发布 了公司自主研发的"慢病管理数智之芯"——杏石医疗大模型。这一重磅发布，不仅是方舟健客对国 家"人工智能+"行动的积极响应，更是为破解"传统慢病管理效率低"、"服务精准度不足"、"医生碎片化 时间难利用"等行业核心难题提供了突破性的技术解决方案，有望成为驱动"AI+慢病管理"领域全面升级 的核心技术底座。 方舟健客重磅发布杏石医疗大模型 作为公司的"超级数字大脑"和"强大智慧中枢"，杏石医疗大模型首先构建了图像语音识别、自然语言理 解、海量医药知识存储及推理思考的底层能力体系。其次，凭借其达到SOTA(State-of-the-Art)水平的医 疗领域大模型性能，它还将知识、导诊、预问诊、医生、电子病历五大智能体聚合成方舟健客的"数智 服务团队"，实现了慢病管理服务全链条闭环覆盖。 作为深耕慢病管理领域的互联网医疗企业，技术创新始终是方舟健客发展的重要基石。从提出业内创新 的"H2H(Hospital To Home)智慧医疗生态"到实现"AI+H2H"重要升级，公司的数智化路径坚定且清晰 ——2022年 ...

9月10日，在方舟健客第十届H2H医疗服务生态大会上，国内领先的AI+慢病管理企业方舟健客 (06086.HK)与信达生物制药集团(以下简称"信达生物")正式签署战略合作协议。方舟健客创始人、董事 长兼首席执行官谢方敏，信达生物全渠道事业部零售副总裁谭再强共同出席签约仪式。 本次战略合作旨在整合方舟健客在AI+慢病管理领域的数智服务能力与信达生物在代谢疾病领域的创新 药物研发优势，携手构建"AI技术+创新产品+精细服务"的数智化合作新模式，为"健康中国2030"战略目 标的实现贡献创新力量。 方舟健客与信达生物此番强强联手，恰值中国减重市场加速发展的关键节点。据摩根大通预计，中国减 肥药物市场规模有望于2030年达到149亿美元(约合人民币1062亿元)。政策层面，2024年6月，国家卫生 健康委等16部门制定并发布了《"体重管理年"活动实施方案》；2025年4月，全国爱卫会发布通知，将 健康体重管理行动等纳入健康中国行动。可见，体重管理已经从个体健康行为上升到国家公共卫生治理 的重要议题。 面对千亿规模的市场机遇，各大药企积极布局、抢占先机。在这一蓝海市场中，如何构建差异化优势、 探索新的解决方案与发展模式 ...